IceCure Medical receives a "Buy" rating with a $3.00 price target from HC Wainwright.

IceCure Medical receives a "Buy" rating from HC Wainwright with a $3.00 price target. HC Wainwright adjusted its Q2 2024 earnings estimate to ($0.07) EPS, up from ($0.08). The company also provided estimates for Q3 2024 at ($0.07) EPS, FY2024 at ($0.29) EPS, and FY2025 at ($0.27) EPS. Shares of ICCM opened at $1.07 with a 12-month low of $0.52 and a 12-month high of $1.57.

June 02, 2024
3 Articles

Further Reading